Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)
There is general agreement that in the treatment of non–small cell lung cancer (NSCLC), patients with stage I or II disease should undergo primary radical surgery. Those with stage III (N2) disease discovered preoperatively should be treated with neoadjuvant chemotherapy or chemoradiotherapy followed by surgery. Therefore, mediastinal staging plays a central role in determining the best treatment modality for patients with NSCLC (De Leyn et al. 2007).